ArgusEye have announced the close of its funding, raising €2.8 million EUR (~£2.4 million GBP) bringing the total raised by the Company to €3.45 million EUR (~£3 million GPB). The funding was led by Voima...

Ensuring patient adherence to medication is a crucial factor in delivering better health outcomes for patients – but adherence for chronic disease is just 50 per cent globally, leading to significant human and economic...

Regeneron Pharmaceuticals have announced that the investigational gene therapy DB-OTO improved hearing to normal levels in one child (dosed at 11 months of age) within 24 weeks, and initial hearing improvements were observed in a...

Metaphore Biotechnologies have joined Flagship Pioneering in announcing a research collaboration with Novo Nordisk to develop up to two next-generation therapeutics for obesity management. Under the terms of the agreement, Novo Nordisk may pay...

Santander UK has provided Ennogen Healthcare International, a growing UK based pharmaceuticals manufacturer, with a £30 million loan facility to support its international expansion plans. Established in 2011, Ennogen is a pharmaceutical and healthcare...

Ribobay Pharma, a leading Chinese biopharmaceutical CRDMO and a spin-off company of General Biol (Anhui) Co., Ltd, will provide cGMP-level oligonucleotide (oligo) CRDMO services to the world using Cytiva’s first FlexFactory platform for oligo manufacturing. It...

Sanofi’s has entered into a co-exclusive licensing agreement with Novavax, a biotechnology company headquartered in Maryland, US. The terms of the agreement include: a co-exclusive license to co-commercialise Novavax’s current stand-alone adjuvanted COVID-19 vaccine worldwide...

Teva Pharmaceuticals and Medincell have announced results from the efficacy portion of the Phase 3 Subcutaneous OLAnzapine extended-Release Injection Study (SOLARIS) trial evaluating TEV-‘749 in adult patients with schizophrenia compared to placebo. Results demonstrated...

Frank Jäger has been appointed Commercial Director of the newly created CCL Clinical business unit. “The fact that the world’s largest label manufacturer, CCL Label, is setting up a business unit dedicated to the...

Lantern Pharma have announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimise the development of its first-in-class protein disulfide isomerase (PDI) inhibitor drug candidate XCE853 in novel and targeted cancer indications. Lantern will be leveraging...